Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Maxingshigansan is a classic Traditional Chinese Medicine (TCM) formula adapted for veterinary use, notably by companies such as Shijiazhuang Yinuo Animal Pharmaceutical. The formula is composed of four primary botanical and mineral ingredients: *Ephedra sinica* (Ma Huang), *Prunus armeniaca* (Xing Ren), *Gypsum fibrosum* (Shi Gao), and *Glycyrrhiza uralensis* (Gan Cao). It is widely utilized in animal health to treat respiratory ailments characterized by lung heat, such as cough, asthma, bronchitis, and pneumonia in livestock and poultry. The therapeutic effect is achieved through the synergistic action of its components, which provide bronchodilation, antitussive, anti-inflammatory, and antipyretic properties. It is typically marketed as a soluble powder or feed additive for oral administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on maxingshigansan.